Transgene S.a.

Sophie Jallat

Michael J Courtney

Jean-Pierre Lecocq

Andrea Pavirani

Frederic Perraud

Pierre Meulien

Luc-Henri Tessier

The invention relates to an analog of human .alpha..sub.1 -antitrypsin characterized in that it is all or part of the protein corresponding to human .alpha..sub.1 -antitrypsin in which, in 358 position, the amino-acid is selected from among arginine and little or non-oxidizable natural amino-acids when they are integrated into a protein.

Derivatives of human .alpha..sub.1 -antitrypsin and process for their

Cell lines have been prepared from transgenic mice comprised of a first exogenous DNA sequence encoding human factor IX which is controlled by a promoter region specific for hepatic cells and a second exogenous DNA sequence encoding an oncogene, such as the SV40 virus gene encoding the T-antigen or the mouse c-myc gene, which is controlled by a promoter region specific for hepatic cells. Promoter regions specific for hepatic cells included the promoter region for the factor IX gene and the promoter region for the .alpha.-1 antitrypsin gene. The cultured cells produce biologically active human factor IX which is then isolated from the culture media.

Cell lines from a transgenic mouse which express biologically active IX

The invention relates to the variant of human alpha.sub.1 -antitrypsin of formula:

Growing community of inventors

Strasbourg, France

Sophie Jallat